Vmbook Online ordering

Mast Therapeutics Inc

Molecular Templates, Inc. (MTEM or the Company) is a clinical-stage biotechnology company focused on the discovery and development of targeted therapeutics. The company's stock is listed on the NASDAQ stock exchange under the ticker symbol "MTEM."

As of my knowledge up to October 2021, MTEM has not yet generated any revenue from product sales. The company's primary focus is on research and development activities, which are supported by financing from public and private sources, including grants, equity financings, and partnerships.

MTEM's product pipeline is based on its proprietary Engager technology, which is designed to selectively deliver payloads to cancer cells while minimizing toxicity to normal cells. The company's lead product candidate, TAK-169, is a CD38 x CD3 Engager that is in a Phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.

In terms of growth, MTEM has been expanding its pipeline and partnerships in recent years. In 2020, the company entered into a collaboration and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize TAK-169. MTEM is also advancing its preclinical programs, including its next-generation Engagers against novel targets.

Regarding financials, MTEM reported a net loss of $25.3 million for the full year 2020, compared to a net loss of $18.4 million for the full year 2019. As of December 31, 2020, MTEM had cash and cash equivalents of $58.4 million.

It is important to note that the biotech industry is subject to significant risks and uncertainties, and there is no guarantee that MTEM's product candidates will be approved by regulatory authorities or achieve commercial success. As a result, investing in MTEM or any biotech company involves a high degree of risk. It is essential to conduct thorough research and consult with a financial advisor before making any investment decisions.